Nanomix, Inc. Appoints Larry K. Wray, Ph.D. As VP Of Development

EMERYVILLE, Calif., Aug. 17, 2015 /PRNewswire/ -- Nanomix Inc., (Nanomix), a leading nanotechnology company focused on the development of next generation mobile diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, today announced the appointment of Larry K. Wray, Ph.D. as Vice President of Development. Dr. Wray, most recently VP of R&D at PerkinElmer, brings significant diagnostic product development and executive experience to Nanomix.

"We are very excited to have Larry join the Nanomix team", said David Ludvigson, President and CEO of Nanomix. "As we drive to the commercial launch of our first product, Larry's product development and management background will be important to the finalization of our products in development and in the expansion of our future offerings."

Dr. Wray has over 25 years of experience in the diagnostics industry including roles with PerkinElmer, Celera, Ventana Medical, and Abbott Laboratories. His experience includes product development of instrument, reagent, and software systems involving molecular diagnostics, immunoassays, and mass spectrometry, as both LDTs and IVDs. He has also been responsible for CE, FDA, and CFDA registrations. Dr. Wray holds a Ph.D. in Genetics from the University of Texas (Austin), an M.S. in Health and Medical Science from University of California (Berkeley), and was an NIH postdoctoral fellow at University of Pennsylvania.

For more information, visit:

Joy Bissell
[email protected] 
Nanomix, Inc.
5980 Horton St, Suite 600
Emeryville, CA 94608 
Phone: 1-510-428-5300

To view the original version on PR Newswire, visit:

SOURCE Nanomix Inc.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.